JP2023512038A5 - - Google Patents

Info

Publication number
JP2023512038A5
JP2023512038A5 JP2022546068A JP2022546068A JP2023512038A5 JP 2023512038 A5 JP2023512038 A5 JP 2023512038A5 JP 2022546068 A JP2022546068 A JP 2022546068A JP 2022546068 A JP2022546068 A JP 2022546068A JP 2023512038 A5 JP2023512038 A5 JP 2023512038A5
Authority
JP
Japan
Prior art keywords
cancer
optionally substituted
compound according
membered
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/015878 external-priority patent/WO2021155264A1/en
Publication of JP2023512038A publication Critical patent/JP2023512038A/ja
Publication of JP2023512038A5 publication Critical patent/JP2023512038A5/ja
Pending legal-status Critical Current

Links

JP2022546068A 2020-01-29 2021-01-29 化合物及びその使用 Pending JP2023512038A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062967346P 2020-01-29 2020-01-29
US62/967,346 2020-01-29
PCT/US2021/015878 WO2021155264A1 (en) 2020-01-29 2021-01-29 Compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2023512038A JP2023512038A (ja) 2023-03-23
JP2023512038A5 true JP2023512038A5 (https=) 2024-01-25

Family

ID=77079270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546068A Pending JP2023512038A (ja) 2020-01-29 2021-01-29 化合物及びその使用

Country Status (4)

Country Link
US (1) US20230121497A1 (https=)
EP (1) EP4096668A4 (https=)
JP (1) JP2023512038A (https=)
WO (1) WO2021155264A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
AU2021213811A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
CN113845436B (zh) * 2021-09-29 2023-08-29 中国科学技术大学 邻膦酚光催化剂用于脱氟烷基化及脱氟质子化反应的方法
AR129299A1 (es) * 2022-05-11 2024-08-07 Foghorn Therapeutics Inc Compuestos para modular complejos de factores asociados a brg1 o brm (baf)
WO2024088351A1 (en) * 2022-10-26 2024-05-02 Suzhou Zanrong Pharma Limited Compounds and uses thereof
WO2024099440A1 (zh) * 2022-11-11 2024-05-16 苏州信诺维医药科技股份有限公司 一种稠环化合物、其用途及含其的药物组合物
CN121443607A (zh) * 2023-07-05 2026-01-30 詹森药业有限公司 可用于治疗smarca4缺陷型癌症的smarca2抑制剂
WO2025008059A1 (en) * 2023-07-05 2025-01-09 Janssen Pharmaceutica Nv 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers
CN121889390A (zh) * 2023-07-05 2026-04-17 詹森药业有限公司 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1,6-萘啶化合物
WO2025008061A1 (en) * 2023-07-05 2025-01-09 Janssen Pharmaceutica Nv 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers
WO2025099307A1 (en) * 2023-11-10 2025-05-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2025209520A1 (zh) * 2024-04-03 2025-10-09 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
WO2000059905A1 (en) * 1999-04-02 2000-10-12 Neurogen Corporation ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
CA2369553A1 (en) * 1999-04-02 2000-10-12 Raymond F. Horvath N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
US7132438B2 (en) * 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
RU2007121864A (ru) * 2004-11-11 2008-12-20 Феррер Интернасионал ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРОВ GABAA, ИЛИ α1-GABAA, ИЛИ α2-GABAA (ВАРИАНТЫ)
WO2006070806A1 (ja) * 2004-12-28 2006-07-06 Taiho Pharmaceutical Co., Ltd. 新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物
AU2007288124B2 (en) * 2006-08-24 2013-04-04 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
EP3022197B1 (en) * 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
CA2935683A1 (en) * 2013-12-30 2015-07-09 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104530013B (zh) * 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
US9932340B2 (en) * 2014-12-18 2018-04-03 Abbvie Inc. Substituted indoles
GB201604638D0 (en) * 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US10207998B2 (en) * 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
TWI791593B (zh) * 2017-08-21 2023-02-11 德商馬克專利公司 做為腺苷受體拮抗劑之苯并咪唑衍生物
US10703748B2 (en) * 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2023512038A5 (https=)
JP2022020003A5 (https=)
CN106572993B (zh) Ep4拮抗剂在制备治疗癌症的药物中的应用
JP2019518741A5 (https=)
CN106470696B (zh) 用于治疗癌症的药物组合
ES2822654T3 (es) Benzimidazol-2-aminas como inhibidores de mIDH1
BR112020008827A2 (pt) moduladores da via de estresse integrada
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
CN105120868A (zh) 组合治疗
BR112019021880A2 (pt) Terapia de combinação com conjugado anticorpo anti-axl-droga
BR112019017612A2 (pt) um inibidor de quinase atr para uso em um método de tratamento de uma doença hiperproliferativa.
WO2010031265A1 (zh) 用于治疗增生性疾病的药物组合物
WO2018122168A1 (en) Combinations of bub1 kinase and parp inhibitors
KR20180013850A (ko) 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
CN118338904A (zh) KRAS G12D抑制剂与PI3Ka抑制剂的组合及相关治疗方法
EP3710456A1 (en) Macrocyclic indole derivatives
JP2024535913A (ja) Ｋｒａｓ変異を有するがん患者の治療
CN118647382A (zh) 治疗异常细胞生长的方法
ES2440799T3 (es) Métodos para tratar cáncer resistente a los fármacos
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
TW202131917A (zh) 併用醫藥
JP2016502540A5 (https=)
CN114786674A (zh) Ahr抑制剂和pd1抑制剂抗体的组合及其在癌症治疗中的用途
WO2018215282A1 (en) Combination of bub1 and pi3k inhibitors
US20250042918A1 (en) Compounds